Drug intelligence / Profile preview

PAS-009

Development stage: Preclinical
Lead developer: Porton Advanced
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

PAS-009 is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Porton Advanced for the treatment of recurrent ovarian carcinoma. The therapy involves engineering a patient's own T cells to express a CAR that specifically recognizes mesothelin, a cell-surface glycoprotein that is highly expressed in several solid tumors, including ovarian cancer. Upon binding to mesothelin on the surface of tumor cells, the CAR-T cells are activated to mediate direct T-cell cytotoxicity, leading to the destruction of the malignant cells. As of early 2024, PAS-009 is in the IND-enabling stage and has received IND approval in China.

Targets

Mesothelin

Beyond the preview

Go deeper on PAS-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAS-009.

Explore the full profile